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Main drugs used in the prevention of stroke among atrial fibrillation 
(AF) patients are antiplatelets (aspirin) and oral anticoagulants (OAC). OAC 
therapy can be difficult to administer due to drug and food interactions, adds 
the burden of required blood monitoring, narrow therapeutic window, and 
requirements for dose titration. Rivaroxaban is a single-dose oral 
anticoagulant which does not require blood monitoring, dose titration or has 
dietary interactions. Phase III clinical data from the ROCKET trial have 
recently been reported the non-inferiority of rivaroxaban over warfarin for 
the prevention of strokes in AF patients. To develop an economic model 
evaluating the clinical and cost-effectiveness of rivaroxaban for the 
prevention of stroke in non-valvular AF patients in the Indonesian health 
care settings. We conducted cost effectiveness analysis from the perspective 
of payer (national health insurance). Effectiveness data used the 
international data from previous RCT and network metaanalysis studies. 
Costs data used local data of Indonesia from national health insurance’s 
reimbursement tariffs. Markov model was used, comprised of health and 
treatment states describing the management and consequences of AF. The 
main analysis was based on data from the phase III trials. Three months was 
used as cycle length. The time horizon was set at patients’ lifetime (20 
years). Costs and outcomes were discounted at a 3% annual rate. Subgroup 
analysis and extensive sensitivity analysis was conducted. Willingness to pay 
(WTP) threshold in Indonesia was set as 3 times GDP of Indonesia in 2015, 
equal about IDR 133,375,000 per quality-adjusted life year (QALY). Base 
case rivaroxaban vs warfarin has ICER of IDR 141,835,063per QALY at the 
current cost of rivaroxaban IDR 23,500 and ICER of 130,214,687 per QALY at 
the proposed cost of rivaroxaban IDR 22,000. One-way sensitivity analysis 
showed that the key drivers of cost-effectiveness were the utility decrement 
applied to stable warfarin patients, discontinuation/subsequent 
discontinuation rates for rivaroxaban, and discontinuation/subsequent 
discontinuation rates for warfarin. The probabilistic sensitivity analysis 
suggested that rivaroxaban was cost-effective compared to warfarin in about 
45% of cases at the WTP per QALY. Rivaroxaban with the proposed price of 
IDR 22,000 was considered to be cost-effective when compared to warfarin. 
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INTRODUCTION 
Atrial fibrillation (AF) is the most common 
arrhythmia and associated with an increased risk 
of ischemic stroke by four to five folds (Reiffeld, 
2014). Stroke caused by AF has higher morbidity 
and mortality than a stroke caused by another 
factor, possibly due to older age and more 
comorbidities in patients with AF-associated 
stroke. The risk of stroke in AF patients increases 
progressively with age, ranging from 1.5% in 50-
59 year group to 23.5% in 80-89 year group 
(Alberts et al., 2012). 
Scoring system is used to assess stroke risk 
in a patient with AF. The most widely used model 
is CHADS2 stratification scheme, consist of five 
independent predictors of stroke risk in patients 
with nonvalvular AF (Congestive heart failure, 
Hypertension, Age ≥ 75 years, Diabetes mellitus, 
and prior Stroke or TIA). The maximum score is 6 
points, with 1 point each for congestive heart 
failure, hypertension, age ≥ 75 years, and diabetes 
mellitus; and 2 points for prior stroke or TIA 
(Furie et al., 2012). This scoring system 
categorizes nonvalvular AF patient to low risk 
(CHADS2 score = 0), moderate risk (CHADS2 score 
= 1), and high risk (CHADS2 score ≥ 2) (Cartman et 
al., 2013). Low-risk patients receive no treatment 
or aspirin, while high-risk patients should receive 
oral anticoagulation. Moderate risk patients can 
either treated by aspirin or oral anticoagulation 
(Cartman et al., 2013; Lane et al., 2012).  
The European Society of Cardiology 
guidelines recommends the use of Vitamin K 
Antagonist (VKA) such as warfarin, or non-VKA 
such as rivaroxaban as oral anticoagulation for 
moderate and high-risk patients (Lip et al., 2014). 
Although warfarin has been standard therapy                 
for high-risk AF patients for decades, it has a 
narrow therapeutic profile, multiple medications 
and food interactions, and requires frequent             
blood coagulation monitoring for controlling                                 
INR between 2.0-3.0 (Reddy et al., 2012). Phase III 
ROCKET-AF trial showed rivaroxaban was non-
inferior to warfarin for prevention of all stroke and 
systemic embolism, and superior to warfarin in 
safety considering its similar rate of overall 
bleeding and lower rates of intracranial bleeding, 
fatal bleeding, and bleeding at critical sites (Fox et 
al., 2011; Morais et al., 2014). 
The objective of this project was to develop 
an economic model evaluating the cost-
effectiveness of rivaroxaban for the prevention of 
stroke in nonvalvular AF patients in the 
Indonesian healthcare setting. The secondary 
objective was to explore the impact on the efficacy 
of alternative interventions in real-life clinical 
practice based on findings from a network meta-
analysis. As Indonesia is moving towards universal 
health coverage since 2014, such economic 
evaluation studies are gaining important as part of 
health technology assessment for healthcare 
decision-making. 
 
MATERIAL AND METHODS 
Model Structures 
The analysis was performed to project the 
long-term cost-effectiveness of treating AF 
patients with rivaroxaban compared to warfarin 
and aspirin for the prevention of stroke in an 
Indonesian setting. The main analysis was based 
on data from the phase III trials. The developed 
model was, therefore, a Markov model, comprised 
of health and treatment states describing the 
management and consequences of AF. Costs and 
outcomes were assigned to each state and used to 
give an output of cost per quality-adjusted-life-
year (QALY). This model was developed in MS 
Excel to ensure transparency and flexibility. 
The population evaluated in the base case 
scenario was similar to the patient population of 
the ROCKET clinical trial. They were patients with 
non-valvular AF and at moderate (CHADS2 risk 
score of 2) to high risk (CHADS2 risk score of 3 or 
higher) of stroke. Patients entered the model 
starting at 60 years of age. 
The following subgroups were considered in 
this model: Current warfarin patients: for this 
subgroup, the payoffs of the therapy initiation step 
could be adjusted so that they do not require 
frequent monitoring; Warfarin-naïve patients; 
Non-warfarin patients (high-risk patients who 
have failed warfarin or never received warfarin 
and received aspirin or no treatment). In addition, 
modules could be set up so that sequence of active 
treatment could be considered, such that a patient 
starting on warfarin might fail and proceeded to 
either receiving aspirin or no treatment; Patients 
managed in different settings (e.g. specialist 
anticoagulation clinic vs. generalist care); Patients 
at high risk of stroke, including those with a 
previous stroke: these can be analyzed by 
adjusting the baseline risk, but the relative 
treatment effects are currently from ROCKET as a 
whole population. 
Patients entered the model with stable 
uncomplicated AF and being treated with one of 
the following interventions: (a) rivaroxaban 20mg, 
once daily (100% patients on 20mg o.d.), followed 
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by aspirin once discontinued, (b) rivaroxaban 
20mg, once daily (100% patients on 20mg o.d.), 
followed by no treatment once discontinued, (c) 
warfarin, target INR of 2.5, 4.5mg, once daily, 
followed by aspirin once discontinued, (d) 
warfarin, target INR of 2.5, 4.5mg, once daily, 
followed by no treatment once discontinued, (e) 
aspirin, recommended dose 75-325mg, one dose of 
160 mg was given in Indonesian practice, or (f) no 
treatment.  Warfarin could also be evaluated using 
an adjusted effectiveness according to INR control 
status. 
Stroke was categorized into minor if it 
resulted in minimum residual sequelae and 
patients were capable of returning to independent 
living, and major, if it required inpatient 
rehabilitation after stabilization with residual 
sequelae which prevented patients from returning 
to independent living. Another way to determine 
stroke severity was by using Rankin scores from 
the ROCKET trial, breaking down the major stroke 
category into moderate and severe strokes, where 
the moderate stroke was defined as Rankin score 
of 3-4, and severe stroke was defined as Rankin 
score of 5. This breakdown was applied to costs 
only, and the utility of a major stroke was applied 




Figure 1. Overall model structure 
 
Patients were always at risk of major 
complications in the model unless they already 
experienced an acute event; patients could not 
experience two acute major complications in the 
same cycle. The major complications under 
consideration in this model were an ischemic 
stroke, systemic embolism, myocardial infarction, 
and bleeding. Death was included as payoffs of 
these complications and as background mortality 
rates. The major events were classified as transient 
events (non-boxed, see Figure 1) or events with 
permanent after-effects (boxed). The intracranial 
(IC) bleeding event might be transient or 
permanent, depends on the stroke risk of the 
population. A high-risk population followed the 
dotted line after experiencing an IC bleed and re-
initiating therapy, while low/medium risk patients 
stayed off anticoagulation in the post- IC bleeding 
state. 
Each health state has a cost and a utility 
weight which describes quality-of-life associated 
as a pay-off. These will be summed with the cohort 
progression and used to calculate the model 
outputs. The cycle length should be short enough 
to sufficiently capture the frequency of major 
events. We used 3 months for the cycle length, as it 
would allow adequate granularity of events and 
costs. Published studies used cycle lengths ranging 
from 30 days to one year. The model’s time 
horizon was set to describe the lifetime of the 
patients (in the model, it was set to 20 years), in 
order to fully incorporate the costs and 
consequences of AF in line with the National 
Institute for Health and Care Excellence (NICE) 
guidelines. Costs and outcomes were discounted at 
a 3% annual rate. Costs were presented in 
Indonesian currency (IDR) in the year 2012. 
The model was constructed for Indonesian 
healthcare setting and captured anticoagulation 
management in a secondary care setting. In 
Indonesia, AF patients are primarily managed by 
specialists in hospitals. Thus the model was 
designed to reflect this approach. 
Baseline epidemiology data applied in the 
model were taken from a range of sources, 
although much of the published data were from 
Europe. However, resource use and costs reflected 
the treatment patterns specific to Indonesian 
healthcare sector. For the present analyses, a 
payer perspective was adopted, however, the 
model is capable of considering a wider societal 
perspective. Productivity loss functionality uses 
the human capital approach. Other parameters 
required for the calculation of indirect costs were 
the average number of days of productivity loss 
(paid) for each type of event and average labor 
cost per day. 
 
Clinical effectiveness and treatment 
discontinuation 
The clinical data inputs were obtained from 
two main sources: the Phase III ROCKET trial or 
the network meta-analysis (NMA) conducted to 
allow comparison of rivaroxaban to non-warfarin 
compa-rators, which were not included in the 
ROCKET trial. Baseline event rates were set as 
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either the warfarin arm rates from the ROCKET 
trial or the placebo   arms   of   clinical   trials   used 
in the NMA.  Relative risk reductions (RRR) were 
then applied, using either treatment effects from 
ROCKET or NMA.  
 
Drug and event cost 
We calculated cost by normative-cost 
approach using the unit cost mostly from national 
health insurance’s reimbursement tariffs and few 
from hospital records. The daily dose of warfarin 
was 2mg, based on KOL opinion. The daily dose of 
aspirin (ASA) for prevention of AF was 160mg.   
Table I and II shows the drug acquisition costs and 
the warfarin monitoring costs used in the model, 
Table III shows the resource use for warfarin 
administration, and Table IV shows the summary 
of the costs and references used for the 
model.Rivaroxaban, aspirin, and dabigatran are all 
fixed-dose oral therapies that do not require any 
additional blood monitoring. Thus, any visits 
related to these therapies were assumed to be 
included    in   routine    care   check-ups.    
Warfarin requires dose-titration and monitoring 
visits over the duration of therapy. It is 
recommended for patients initiated with warfarin 
for the first time, or after a period of therapy 
interruption, to see a physician regularly and 
frequently to adjust the dose of warfarin until the 
INR is stable, which has a target therapeutic range 
between 2.0 to 3.0. Once the INR is stabilized, the 
number of visits may be decreased, but are still 









     
Warfarin (2mg) 979 2mg/day 979 E-catalogue (Presidential Regulation, 
2014; MoH Regulation, 2014) 
Aspirin (80mg) 116 160mg/day 232 E-catalogue (Presidential Regulation, 
2014; MoH Regulation, 2014) 
Clopidogrel (75mg) 3,400 75mg/day 3,400 E-catalogue (Presidential Regulation, 
2014; MoH Regulation, 2014) 
Rivaroxaban (20mg) 23,500 20mg/day 23,500 E-catalogue (Presidential Regulation, 
2014; MoH Regulation, 2014) 
Dabigatran 12,936  25,872 E-catalogue (Presidential Regulation, 
2014; MoH Regulation, 2014) 
 
Table II. Costs for warfarin administration 
 
Item Unit Cost Low High Reference 
Warfarin Monitoring Visit  (first ever)  140,850  121,288   167,977  Hospital records (high) 
Warfarin Monitoring Visit (subsequent) 121,288 - - Hospital records (high) 
GP based warfarin monitoring - - - N/A 
Check-ups for other therapy - - - N/A 
Patient Transport Service  - - - N/A 
% of patients using transport (payer perspective) - - - Not reimbursed 
 
Table III. Resource use for warfarin administration 
 
Item Frequency over three months Reference 
Therapy Initiation Period 12 KOL 
Warfarin Monitoring Visit (maintenance phase) 3 BPJS Health 
insurance  
Therapy Re-initiation 4 BPJS Health 
insurance  
Monitoring visits for novel OAC and aspirin users 0 Assumption 
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required due to the fact that warfarin efficacy is 
influenced by many factors, including concomitant 
medication and diet. When patients were re-
initiated on therapy, it was assumed that there 
were some records of the last dose at which the 
patient remained stable, and thus re-titration 
would require less frequent visits. The assumption 
for the number of visits required for re-initiation 
was based on KOL opinion. The cost per visit 
differs according to the setting of care where 
monitoring takes place, whether in general 
practitioner (GP) office or in the specialised 
anticoagulation clinic.  In the present model, 100%  
patients were assumed to be treated in 
anticoagulation clinics in addition, the model has 
the option of incorporating a cost for using patient 
transport services to attend anticoagulation clinics. 
This was not applied for Indonesia as travel costs 
are not reimbursed. 
 
Health-related outcomes 
We used health utility data from previous 
studies in other settings. These studies used 
various methods to elicit preference including 
single measurement using standard gamble                 
and   multi-attribute   measurement    using   EQ5D. 
Table IV. A summary of the costs and references used for the model 
 
Event 
Base case cost 
(IDR) 
Low (IDR) High (IDR) Source 
Stroke Treatment Costs     
Acute Treatment – minor  9,026,200  7,521,800  10,530,500  INA CBG 2016 Java-Bali region 
(MoH Regulation,2016) 
Acute Treatment – major  15,145,900  12,621,600  17,670,200  INA CBG 2016 Java-Bali region 
(MoH Regulation, 2016) 
Acute Treatment – excess days N/A    
Follow-on Care (per quarter) – 
major stroke 
 336,085   74,338   757,071  Hospital records 
Rehabilitation Costs per day  58,204   29,344   195,626  BPJS Health insurance  
Bleed Treatment Costs     
Acute Treatment – minor  9,254,263   7,711,886  10,796,640  INA CBG 2016, Java-Bali region 
(MoH Regulation, 2016) 
Acute Treatment – major  39,512,583  32,927,153  46,098,014  INA CBG 2016, Java-Bali region 
(MoH Regulation, 2016) 
Acute Treatment – IC bleed  8,763,300   7,302,700  12,254,000  INA CBG 2016, Java-Bali region 
(MoH Regulation, 2016) 
Follow-on Care (per quarter) – 
IC bleeds 
 336,085   74,338   757,071  Hospital records 
Rehabilitation Costs (per 
quarter) 
 465,631   29,344   195,626  Assumption [Eight days of 
rehabilitation (similar with major 
stroke) at the same cost as post-
ischaemic stroke rehabilitation] 
SE treatment costs     
Acute treatment  5,902,700   4,919,000  13,020,100  INA CBG 2016  Java-Bali, TIA as a 
proxy for systemic embolism 
(MoH Regulation, 2016) 
MI treatment costs     
Acute treatment  12,241,100   5,712,800  20,577,400  INA CBG 2016  Region 1, average 
of inpatient hospital class and 
severity (MoH Regulation, 
2016) 
Follow-on care (per quarter)  673,000  641,000   973,300  INA CBG 2016  Region 1, average 
of outpatient hospital class                  
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A systematic search was performed to identify 
health state utility values in stable AF, stroke, post-
stroke, embolism, myocardial infarction, and 
bleeding events in a non-valvular AF population. 
Utility value for stable untreated AF represents the 
baseline untreated state of an AF patient who is 73 




The model has the capability of 
incorporating analyses for various subgroups.            
The potential subgroups described in the sub-
headings below have been identified and 
incorporated        into the model: (a) VKA-difficult – 
high resource use, (b) VKA-difficult – poor INR 
control, (c) VKA-difficult – high resource use and 
poor INR control, (d) non-VKA users, (e) high risk 
of stroke, (f) prior stroke, (g) VKA-naïve, and (h) 
“user defined”.  
For the high risk of stroke, prior stroke, and 
VKA-naïve sub-groups, relative risks were taken 
from the ROCKET trial (Table VI). The model was 
set up to use the relative risks from either the 
safety on-treatment or the intent-to-treat ROCKET 
populations, depending on which was selected. For 
the three VKA difficult sub-groups and the non-
VKA use sub-group, the relative risks used were 
based on assumptions (Table V). The ones below 
are based on SoT data. 
The distribution of patient INR status                 
for   patients  receiving  warfarin   treatment  in         an  
 
anticoagulation clinic setting was based on Yousef 
et al., (2004) study and those receiving warfarin 
monitoring via a general practice settings was 
based on Dolan et al. (2008) study. 
 
Sensitivity analysis 
Extensive sensitivity analyses were carried 
out in order to evaluate the findings of the             
model. One-way sensitivity analyses were carried 
out to test the impact of varying key parameters on 
the model outcomes to a worst/best case            
scenario. Key parameters were varied to low and 
high values within plausible ranges. For 
parameters such as clinical efficacy values               
which are based on robust studies or reviews,             
the reported 95% CI was used. For parameters            
for which there are still uncertainties surrounding 
the source data, ranges reported in the               
literature were used, in order to ascertain the 
potential outcome a different data source                
should be selected. For cost and resource               
inputs, ranges provided by Bayer were                  
applied. 
The probabilistic sensitivity analysis (PSA) 
is a stochastic analysis conducted to test second-
order uncertainty in the model and evaluates the 
model for overall robustness. For this purpose, 
random values are simulated in 500 iterations. 
Random values for each of the key parameters of 
the model were extracted from a probability 
distribution characterizing the range of expected 
values of each variable. 
 
Table V. Summary of base case utilities 
 
Health State Utility Source 
Utility: Stable AF – not on treatment 0.78  Berg et al. 2010 
Utility: Stable AF – on warfarin treatment 0.94 Robinson et al.2001 
Utility: Stable AF – on other therapy 0.78 Berg et al. 2010  
Utility Decrement: Initiating Warfarin treatment 0.94 Robinson et al. 2001 
Utility: Minor Stroke  0.64  Robinson et al.2001  
Utility: Post Minor Stroke 0.72 Berg et al 2010 
Utility: Major Stroke 0.19  Robinson et al. 2001 
Utility: Post Major Stroke 0.48 Berg et al 2010 
Utility: Systemic Embolism 0.66 
Sullivan et al. 2006 Utility: Minor Bleed 0.78  
Utility: Major Bleed 0.60  
Utility: Intracranial Bleed 0.60 Lenert et al. 1997 
Utility: Post IC Bleed 0.74 Haacke et al. 2006 
Myocardial Infarction  0.68 Lacey et al. 2003 
Post Myocardial Infarction 0.69 Sanders et al. 2001 
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RESULT AND DISCUSSION 
One-way sensitivity analysis (Figure 2) 
shows that the key drivers of cost-effectiveness 
between rivaroxaban vs warfarin based on cost 
per QALY were the utility decrement applied to 
stable warfarin patients, discontinuation/ 
subsequent discontinuation rates for rivaroxaban, 
and discontinuation/subsequent discontinuation 
rates for warfarin. PSA results are showed as cost-
effectiveness acceptability curves (CEACs) (Figure 
3). The willingness-to-pay (WTP) threshold in 
Indonesia, which is three times the gross domestic 
product (GDP) per capita, is IDR 133.375.000 per 
QALY. Indonesia per capita GDP used in this study 
referred to the World Bank data in the year 2015, 
which was USD 3,347). The WTP threshold used at 
the time the study was conducted with the 
currency rate of 1 USD = IDR 13,285. The CEAC 
curve shows that, based on 1000 iterations, 
rivaroxaban was cost-effective compared to 
warfarin in about 45% of cases at the WTP per 
QALY of IDR 133.375.000.   
This cost-effectiveness study in Indonesian 
setting using the payer’s perspective showed            
that, when compared with warfarin, treatment 
with   rivaroxaban   led  to  an  ICER lower than  the  
Table VI. Clinical effectiveness 
 
Event Risk relative to RR  CI Source 
Relative risk data inputs for High-Risk Stroke sub-group 
Ischemic stroke Warfarin 0.93 0.74 – 1.18 ROCKET 
Systemic embolism Warfarin 0.21 0.07 – 0.62 ROCKET 
Major Bleed Warfarin 1.11 0.94 – 1.32 ROCKET 
Intracranial bleed Warfarin 0.65 0.45 – 0.93 ROCKET 
Relative risk data inputs for Prior Stroke sub-group 
Ischemic stroke Warfarin 1.0 0.73 – 1.37 ROCKET 
Systemic embolism Warfarin 0.36 0.23 – 0.46 ROCKET 
Major Bleed Warfarin 1.66 0.82 – 3.35 ROCKET 
Intracranial bleed Warfarin 2.28 1.04 – 4.99 ROCKET 
Relative risk data inputs for VKA Naïve sub-group 
Ischemic stroke Warfarin 0.91 0.63 – 1.30 ROCKET 
Systemic embolism Warfarin 0.14 0.02 – 1.15 ROCKET 
Major Bleed Warfarin 1.02 0.77 – 1.34 ROCKET 
Intracranial bleed Warfarin 0.57 0.34 – 0.96 ROCKET 
Relative risk data inputs for VKA difficult – High Resource Use sub-group 
Ischemic stroke Warfarin 0.94 0.75 – 1.17 Assumption 
Systemic embolism Warfarin 0.23 0.09 – 0.61 Assumption 
Major Bleed Warfarin 1.14 0.98 – 1.33 Assumption 
Intracranial bleed Warfarin 0.67 0.47 – 0.93 Assumption 
Relative risk data inputs for VKA difficult – poor INR control sub-group 
Ischemic stroke Warfarin 0.94 0.75 – 1.17 Assumption 
Systemic embolism Warfarin 0.23 0.09 – 0.61 Assumption 
Major Bleed Warfarin 1.14 0.98 – 1.33 Assumption 
Intracranial bleed Warfarin 0.67 0.47 – 0.93 Assumption 
Relative risk data inputs for VKA difficult – high resource use and poor INR control sub-group 
Ischemic stroke Warfarin 0.94 0.75 – 1.17 Assumption 
Systemic embolism Warfarin 0.23 0.09 – 0.61 Assumption 
Major Bleed Warfarin 1.14 0.98 – 1.33 Assumption 
Intracranial bleed Warfarin 0.67 0.47 – 0.93 Assumption 
Relative risk data inputs for Non-VKA users sub-group 
Ischemic stroke Placebo 0.32 0.10 – 0.74 Assumption 
Systemic embolism Placebo 0.41 0.03 – 3.79 Assumption 
Major Bleed Placebo 3.83 0.84 – 17.04 Assumption 
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Table VII. Cost-effectiveness ratio 
 
Scenario 
Price of Rivaroxaban at the time of 
analysis (IDR 23,500) 








Total cost (IDR) 47,789,630 21,689,839 45,651,306 21,689,839 
Total QALY 4.79 4.61 4.79 4.61 
Incremental cost (IDR) 26,099,792  23,961,467  
Incremental QALY 0.18   0.18   
ICER (IDR per QALY) NA Rivaroxaban vs Warfarin 
141,835,063 











Figure 3. Cost-effectiveness acceptability curve of rivaroxaban vs warfarin 
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Indonesian WTP of IDR 133.375.000 per 
QALY.Given the economic variation across 
Indonesia, it is likely that in some regions 
rivaroxaban will represent a cost-effective 
treatment for SPAF. 
A study in Belgian setting, which also took 
the payer perspective and based on the results of 
the ROCKET trial, showed almost similar results. 
The incremental QALY was lower in the Belgian 
setting,  but  the incremental cost was higher in the  
Indonesian setting, due to significant different in 
drug acquisition cost. In Belgian setting, 
rivaroxaban was cost-effective compared to 
warfarin to prevent stroke in AF patients. The ICER 
of rivaroxaban compared to warfarin was quite 
similar with that in the Indonesian setting (EUR 
8,809 per QALY, or around IDR 131.1 million per 
QALY). However, the Belgian WTP is higher; and 
even the lowest WTP, EUR 10,000 (= IDR 149 
million) in the sensitivity analysis gave 66% cases 
in which rivaroxaban will be more cost-effective 
than warfarin (Kleintjens et al., 2013). Another 
study in the United States of America (USA) with 
similar   perspective   showed   that  rivaroxaban  is 
cost-effective compared to warfarin in preventing 
stroke in AF patients. The ICER for rivaroxaban vs 
warfarin was USD 27,498 per QALY (= IDR 365.3 
million), but the USA WTP was considerably higher 
than the Indonesian WTP, resulting in the cost-
effectiveness of rivaroxaban over warfarin (Lee et 
al., 2012). A study in Singaporean setting, with a 
slightly different perspective from health care 
system, showed a higher ICER (USD 26,727 per 
QALY or IDR 355.1 million) compared to this 
study, with a higher WTP of USD 58,500 (IDR 
777.1 million), leads to the cost-effectiveness of 
rivaroxaban compared to warfarin (Wang et al., 
2014). 
One-way sensitivity analysis in this study 
showed the key drivers of the high ICER.                          
When compared with warfarin, the drivers            
were the utility decrement applied to stable 
warfarin patients, discontinuation/subsequent 
discontinuation rates for rivaroxaban, and 
discontinuation/subsequent discontinuation rates 
for warfarin.Meanwhile, the PSA showed that, with 
the current WTP, rivaroxaban with the lower 
offered price was cost-effective compared to 
warfarin.   
The results of the sensitivity analyses 
conducted in the base case model settings and 
other scenarios indicated that model findings were 
sensitive to a range of parameters in the model. 
Notably, many sensitivity analyses returned ICERs 
below the WTP for Indonesia. Nonetheless, it 
should be considered that uncertainty in cost and 
resource inputs had a limited impact on findings. 
During model development, it was also noted that 
a high rate of background mortality limited 
opportunities to benefit from stroke prevention in 
AF patients. As progress is made to reduce 
background mortality in Indonesia, it is likely that 
the treatment with rivaroxaban will become more 
cost-effective.  
It should be considered that base case 
comparisons against warfarin were made using the 
SOT data set. The safety of treatment is more 
representative of efficacy in clinical practice but is 
less conservative. A scenario analysis using ITT 
data led to a small increase in the base case ICER. 
Rivaroxaban is a new oral anticoagulant that 
offers physicians and patients an opportunity to 
bridge the treatment gap in AF due to suboptimal 
warfarin use. Rivaroxaban successfully demons-
trated non-inferiority compared to warfarin for the 
prevention of stroke and systemic embolism and 
was similar to warfarin on the principal safety 
outcome of major and non-major clinically 
relevant bleeding. Patients in the rivaroxaban arm 
of the ROCKET AF study also had favorable 
cardiovascular outcomes relative to warfarin, with 
a statistically significant 15% relative risk 
reduction in the pre-specified composite 
secondary endpoint of stroke, non-CNS systemic 
embolism, myocardial infarction and vascular 
death. In addition, rivaroxaban showed a trend to 
lower rates of MI, vascular death, and all-cause 
mortality compared with warfarin (Patel, 2011). 
This study have some limitations. First, this 
study used health utility parameters from other 
settings, not from Indonesian measurement. This 
might influence the result of study since the health 
utility is influenced by socio-demographic of 
population. Second, this economic evaluation study 
used modelling approach to evaluate the cost 
effectiveness of rivaroxaban compared to warfarin, 
in which some uncertainties are possible. 
However, we also presented sensitivity analysis 
results of the study. 
 
CONCLUSION 
The cost-effectiveness analysis showed that 
rivaroxaban with the offered price is cost-effective 
compared to warfarin in Indonesian healthcare 
setting. This study was run with a price per day of 
rivaroxaban of IDR 23,500. Under consideration of 
an EJP of IDR 22,000 per day, the cost-
effectiveness will be improved.  
Iwan Dwipahasto 
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